Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis, cirrhosis, and healthy control participants also need to show the evolution of tumors and discover specific diagnostic markers as a control group. Moreover, targeted therapy and immunotherapy make cancer treatment enter a new field, but only part of patients achieve response rates and reach clinical benefit. However, these drugs are expensive and can cause treatment-related adverse events. Therefore, reliable biomarkers identification is needed to help predict the response to these treatment options in order to screen patients with better responsiveness and avoid wasting money. Multi-omics research can reveal the characteristics of hepatobiliary tumors more deeply and find meaningful therapeutic targets.
Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Be older than 18 years old;
✓. ECOG 0-2 points;
✓. May have received treatment;
✓. Clinical consideration or diagnosis of benign and malignant hepatobiliary tumors; or chronic hepatitis, cirrhosis, or healthy control participants;
✓. Patients may have received or are about to undergo surgery, chemotherapy, radiotherapy, targeted therapy, local therapy, immunotherapy, etc.;
✓. Patients understand and are willing to sign written informed consent documents.
Exclusion criteria
✕. The doctor thinks it is not suitable to enter the group (mental disorder or poor compliance, etc.)
✕. Pregnant women;
✕. Active or uncontrollable infections (fungi, bacteria, etc.);
✕. Estimated survival time \<12 weeks;
What they're measuring
1
Collected samples
Timeframe: through study completion, an average of 5 years